Seres Therapeutics presents three posters at DDW Conference

Seres Therapeutics (MCRB) will present three related posters at the upcoming 2025 Digestive Disease Week Conference being held May 3-6, 2025, in San Diego, CA. Seres previously reported exploratory translational biomarker data from its SER-155 Phase 1b study, which provided evidence supporting the intended therapeutic mechanisms. These included promoting intestinal epithelial barrier integrity to reduce the translocation of bacteria and inflammatory bacterial products into the bloodstream, as well as modulating systemic inflammatory responses. New results presented at the DDW conference could help identify candidate biomarkers to support the further clinical development of live biotherapeutics to treat inflammatory and immune diseases, including ulcerative colitis and Crohn’s disease. Seres is currently seeking partnership opportunities to advance the development of its biotherapeutics in inflammatory and immune diseases.